glp-1 drug makers How medications are transforming diabetes and weight loss treatment 2025’s Breakthrough GLP-1 Obesity Treatments:

For example, semaglutide and empagliflozin showed no significant difference in 3-point MACE (HR 1.05

World Health Organization

We report an unusual case of diabetic ketoalkalosis, a mixed acid-base disorder, in a 57-year-old female patient with insulin-dependent T2DM following a switch to Mounjaro (tirzepatide)

Interestingly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), used in the treatment of T2DM and obesity, are known to show pro-cognitive and neuroprotective properties, and exert modulatory effects on immune, endocrine and metabolic processes in the central nervous system

Learn about the link between GLP-1 medications, rapid weight loss, and hair thinning.

Drug safety isnt just about innovation